AriBio says its pill slowed Alzheimer’s decline by 31% in a trial group


The company says the result applied to 604 participants taking no specified Alzheimer’s medicines at the start; the finding was not statistically significant across all 1,535 participants.
AriBio says its experimental pill AR1001 slowed clinical decline by 31% compared with a placebo over 52 weeks in people with early Alzheimer’s who were not taking an acetylcholinesterase inhibitor or memantine at the start. Those medicines are used to treat Alzheimer’s symptoms. AriBio is a South Korean biotechnology company developing treatments for neurodegenerative diseases, and AR1001 is its lead investigational program.
The result in that group was statistically significant, but the result across the full trial favored AR1001 numerically without reaching statistical significance. The preliminary findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.
AR1001 remains investigational for Alzheimer’s. Its safety and effectiveness for that use have not been established, and experts said it needs scientific and regulatory scrutiny before it could be prescribed for the disease.
The Phase 3 POLARIS-AD trial enrolled people across 13 countries. Participants were randomly assigned to take either 30 mg of AR1001 or a placebo once a day. Neither participants nor researchers knew who received which during the main study.
A trial listing specifies participants aged 55 to 90 with mild cognitive impairment or mild dementia consistent with Alzheimer’s, as well as a positive test for an amyloid marker in the brain.
In the group not taking the specified medicines, the difference was 0.44 points on the Clinical Dementia Rating–Sum of Boxes, a scale measuring thinking and daily functioning. The trial plan specified that group and the overall population in advance as two primary groups, each with its own threshold for statistical significance.

Fosun Pharma, a pharmaceutical company that published details of the findings, said most adverse events during treatment were mild to moderate. An adverse event is a health problem recorded during a study and is not necessarily caused by the drug.
| Measure | AR1001 | Placebo |
|---|---|---|
| Participants with an adverse event | 69.0% | 66.4% |
| Participants with a serious adverse event | 10.0% | 9.8% |
AR1001 is a phosphodiesterase-5 inhibitor, in the same family of medicines as Viagra. Sheona Scales, director of research at Alzheimer’s Research UK, said that rather than targeting amyloid, it acts on a specific enzyme and influences other processes involved in brain function. She described the findings as very encouraging but noted that the benefit was not statistically significant across the overall trial group.
Richard Oakley, associate director of research and innovation at Alzheimer’s Society, told The Guardian that people should not take Viagra to try to treat Alzheimer’s. “AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer’s disease,” he said.
Fosun Pharma said more than 95% of eligible participants who completed the main study entered an optional 52-week open-label extension in which everyone receives AR1001. Further safety findings could change how the results are interpreted. The extension is expected to conclude in Q3 2027, and AriBio plans to discuss the complete findings with the US Food and Drug Administration to determine the next steps.

United Launch Alliance says early data point to low first-stage performance after liftoff. The November 15 failure resulted in the loss of 40 Amazon Leo satellites; the cause remains under investigation.
3 min

Science Corporation says the Khosla Ventures-led round will help prepare a US launch for PRIMA. The company says the US Food and Drug Administration granted the retinal implant rare-condition status for patients blind in both eyes from advanced geographic atrophy caused by age-related macular degeneration, with no vision loss from another eye disease. US approval is still pending.
3 min

The watchdog found that some ads overstated links between common symptoms and low testosterone and that a Facebook ad’s claim it affects 25% of men over 30 lacked evidence. Voy says it won’t run the ads again.
3 min